ボディコントゥアリング治療の世界市場：製品別、タイプ別、用途別、エンドユーザー別 - 予測（～2029年）

世界のボディコントゥアリング治療の市場規模は、2024年の14億6,000万米ドルから2029年までに25億8,000万米ドルに達し、2024年～2029年のCAGRは10.0%に達すると予測されています。

美容施術の受け入れが増加し、パーソナライズされた柔軟な資金調達プランもあり、これらの製品に対する需要が高まっています。アンチエイジング施術への関心の高まりは、高齢者に浸透しています。身体の輪郭を整える施術は、体型を整え、自信を向上させるのに役立ちます。さらに、低侵襲的および非侵襲的ボディコントゥアリング施術の利点の増加は、ボディコントゥアリング治療市場の需要を促進しています。

「技術別では、非侵襲的技術セグメントが2023年に市場で最大のシェアを占めました。」

非侵襲的技術が2023年に大きなシェアを占めました。技術革新の増加、広告の増加、より少ない切開によるデバイスの採用の高まりが、このセグメントの成長を促進すると予測されています。高周波、超音波、冷却脂肪溶解（脂肪の冷凍）、レーザーベースの技術を含む非侵襲的なボディコントゥアリング治療は、安全性と有効性の面で大幅に改善されています。これらの技術には幅広い利点があり、これが非侵襲的治療が人気を博している要因となっています。

「用途別では、非手術脂肪減少セグメントが2023年に市場で最大のシェアを占めました。」

美容センターの増加と、主に精度の向上とよりよい結果による採用率の向上が市場を牽引しています。非手術脂肪減少治療はすべての患者タイプと年齢にわたって人気を集めています。それゆえ、革新的な技術による治療施術への幅広い受け入れは、さらに非手術脂肪減少セグメントの成長を促進する需要の急増を後押ししています。

「患者タイプ別では、女性患者セグメントが2023年に最大の市場シェアを占めました。」

非侵襲的なボディコントゥアリング施術に関する認知度の向上や、妊娠後の身体再建術の増加、インフルエンサーの推奨の増加、ソーシャルメディアプロモーションがこのセグメントの成長を支えています。

「エンドユーザー別では、美容クリニックセグメントが予測期間に大きなCAGRを記録する見込みです。」

2023年に病院が大きなエンドユーザーの市場シェアを占めています。ボディコントゥアリング施術への支出の増加、メディカルツーリズムの増加、1人当たりの可処分所得の増加が、このセグメントの成長を促進すると予測されています。さらに、病院における新しく改良された機器の採用の増加も、このセグメントの成長を後押しすると予測されます。

「アジア太平洋は予測期間にもっとも高い成長が見込まれます。」

北米が2023年に大きなシェアを占めました。アジア太平洋はボディコントゥアリング治療市場でもっとも高いCAGRで成長します。特に新興経済国では、医療インフラとサービスへの投資が医療美容の開発を促進し、ボディコントゥアリングの需要の増加につながっています。この点で、マーケットリーダーはアジア太平洋市場におけるプレゼンスを強化する活動を強めており、増大し続けるボディコントゥアリング治療の需要に応えています。また、特にアジア太平洋において、美容クリニックのプレゼンスが増すことで、この市場におけるサービスの利用可能性とアクセシビリティも向上しています。

当レポートでは、世界のボディコントゥアリング治療市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

• ボディコントゥアリング治療市場の概要
• 北米のボディコントゥアリング治療市場：技術別
• アジア太平洋のボディコントゥアリング治療市場：エンドユーザー別
• 欧州のボディコントゥアリング治療市場：用途別
• ボディコントゥアリング治療市場の地理的スナップショット

第5章 市場の概要

• イントロダクション
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
• バリューチェーン分析
  • 研究・製品開発
  • 原材料調達、製造
  • 流通、マーケティング、販売、アフターサービス
• サプライチェーン分析
  • メーカー
  • エンドユーザー
• エコシステム分析
• 規制分析
  • 規制情勢
  • 規制当局の承認
  • 主な規制機関、政府機関、その他の組織
• 償還シナリオ分析
• 投資と資金調達のシナリオ
• 価格分析
  • 主要企業の平均販売価格：技術別
  • ボディコントゥアリングデバイスの平均販売価格：地域別
• 貿易分析
  • 輸入データ
  • 輸出データ
• 特許分析
• ポーターのファイブフォース分析
• 主なステークホルダーと購入基準
• 主な会議とイベント（2025年～2026年）
• ケーススタディ分析
• 技術分析
  • 主要技術
  • 補完技術
  • 隣接技術
• 顧客ビジネスに影響を与える動向/混乱
• アンメットニーズ
• ボディコントゥアリング治療市場に対するAI/生成AIの影響

第6章 ボディコントゥアリング治療市場：技術別

• イントロダクション
• 侵襲的技術
• 非侵襲的技術

第7章 ボディコントゥアリング治療市場：性別

• イントロダクション
• 女性患者
• 男性患者

第8章 ボディコントゥアリング治療市場：用途別

• イントロダクション
• 非手術脂肪除去
• セルライト除去
• 脂肪吸引
• 腹部整形
• その他の用途

第9章 ボディコントゥアリング治療市場：エンドユーザー別

• イントロダクション
• 病院
• 美容クリニック
• メディカルスパ・美容センター

第10章 ボディコントゥアリング治療市場：地域別

• イントロダクション
• 北米
  • 北米のマクロ経済の見通し
  • 米国
  • カナダ
• 欧州
  • 欧州のマクロ経済の見通し
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • アジア太平洋のマクロ経済の見通し
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ラテンアメリカのマクロ経済の見通し
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
• 中東・アフリカ

第11章 競合情勢

• 概要
• 主要参入企業の戦略/強み
• 収益分析（2019年～2023年）
• 市場シェア分析（2023年）
• 企業の評価マトリクス：主要企業（2023年）
• 企業の評価マトリクス：スタートアップ/中小企業（2023年）
• 企業の評価と財務指標
• ブランド/製品の比較
• 競合シナリオ

第12章 企業プロファイル

• 主要企業
  • ABBVIE INC.
  • INMODE LTD.
  • BAUSCH HEALTH COMPANIES INC.
  • CYNOSURE LUTRONIC
  • SISRAM MEDICAL LTD
  • CUTERA, INC.
  • EL.EN. S.P.A.
  • VENUS CONCEPT
  • SHARPLIGHT TECHNOLOGIES INC.
  • SCITON
  • CANDELA CORPORATION
  • BTL INDUSTRIES
  • FOTONA
  • GZ MTS ELECTRONICS CO., LTD.
  • ROHRER AESTHETICS, INC.
• その他の企業
  • GBS INTERNATIONAL HOLDING LTD.
  • SINCLAIR
  • THERMI
  • YOLO MEDICAL INC.
  • DOMINION AESTHETIC TECHNOLOGIES, INC.
  • ZIMMER MEDIZIN SYSTEME GMBH
  • ERCHONIA CORPORATION
  • CLASSYS INC.
  • WON TECH CO., LTD.
  • CELLSOUND AESTHETICS

第13章 付録

List of Tables

• TABLE 1 BODY CONTOURING TREATMENTS MARKET: INCLUSIONS AND EXCLUSIONS
• TABLE 2 SURGICAL PROCEDURES PERFORMED ON MALE PATIENTS, 2021-2023
• TABLE 3 NON-SURGICAL PROCEDURES PERFORMED ON MALE PATIENTS, 2021-2023
• TABLE 4 NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023 (US, GERMANY, FRANCE, GREECE)
• TABLE 5 NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023 (BELGIUM, MEXICO, COLOMBIA, IRAN)
• TABLE 6 NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023 (UK, SPAIN, ARGENTINA, PERU)
• TABLE 7 NON-SURGICAL PROCEDURES, BY COUNTRY, 2023 (GERMANY, FRANCE, BELGIUM, GREECE)
• TABLE 8 NON-SURGICAL PROCEDURES, BY COUNTRY, 2023 (US, UK, COLOMBIA, IRAN)
• TABLE 9 NON-SURGICAL PROCEDURES, BY COUNTRY, 2023 (MEXICO, SPAIN, ARGENTINA, PERU)
• TABLE 10 AESTHETIC PLASTIC SURGEON FEES IN NORTH AMERICA, 2022 VS. 2023
• TABLE 11 NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023
• TABLE 12 NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023
• TABLE 13 NON-SURGICAL PROCEDURES, BY COUNTRY, 2023
• TABLE 14 NON-SURGICAL PROCEDURES, BY COUNTRY, 2023
• TABLE 15 BODY CONTOURING TREATMENTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 16 US: MEDICAL DEVICE CLASSIFICATION
• TABLE 17 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
• TABLE 18 US: CLASSIFICATION OF BODY CONTOURING DEVICES
• TABLE 19 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
• TABLE 20 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
• TABLE 21 CHINA: CLASSIFICATION OF MEDICAL DEVICES
• TABLE 22 REGULATORY APPROVALS FOR BODY CONTOURING DEVICES, BY COUNTRY
• TABLE 23 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 24 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 25 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 26 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 27 MIDDLE EAST & AFRICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 28 MEDICAL REIMBURSEMENT CODES FOR BODY CONTOURING PROCEDURAL SERVICES IN US, 2023
• TABLE 29 AVERAGE SELLING PRICE OF KEY PLAYERS, BY TECHNOLOGY, 2024 (USD)
• TABLE 30 AVERAGE SELLING PRICE OF BODY CONTOURING DEVICES, BY REGION, 2022-2024 (USD)
• TABLE 31 IMPORT DATA FOR BODY CONTOURING DEVICES (HS CODE 9018), BY COUNTRY, 2019-2023 (USD THOUSAND)
• TABLE 32 IMPORT DATA FOR LASERS (EXCLUDING LASER DIODES) (HS CODE 901320), BY COUNTRY, 2019-2023 (USD THOUSAND)
• TABLE 33 EXPORT DATA FOR BODY CONTOURING DEVICES (HS CODE 9018), BY COUNTRY, 2019-2023 (USD THOUSAND)
• TABLE 34 EXPORT DATA FOR LASER (EXCLUDING LASER DIODES) (HS CODE 901320), BY COUNTRY, 2019-2023 (USD THOUSAND)
• TABLE 35 INNOVATIONS AND PATENT REGISTRATIONS, JANUARY 2021-AUGUST 2024
• TABLE 36 BODY CONTOURING TREATMENTS MARKET: PORTER'S FIVE FORCES
• TABLE 37 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF BODY CONTOURING PRODUCTS
• TABLE 38 INFLUENCE OF END USERS ON BUYING PROCESS, BY END USER
• TABLE 39 BODY CONTOURING TREATMENTS MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
• TABLE 40 BRAND MAPPING OF THERMAL TECHNOLOGIES
• TABLE 41 BRAND MAPPING OF NON-THERMAL TECHNOLOGIES
• TABLE 42 BODY CONTOURING TREATMENTS MARKET: CURRENT UNMET NEEDS
• TABLE 43 BODY CONTOURING TREATMENTS MARKET: INTENSITY OF CURRENT UNMET NEEDS
• TABLE 44 BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 45 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 46 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 47 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE RADIOFREQUENCY TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 48 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE LASER TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 49 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE ULTRASOUND TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 50 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 51 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 52 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE RADIOFREQUENCY TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 53 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE LASER TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 54 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE ULTRASOUND TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 55 BODY CONTOURING TREATMENTS MARKET FOR CRYOLIPOLYSIS TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 56 BODY CONTOURING TREATMENTS MARKET FOR OTHER NON-INVASIVE TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 57 BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
• TABLE 58 BODY CONTOURING PROCEDURES IN FEMALE PATIENTS, 2022 VS. 2023
• TABLE 59 BODY CONTOURING TREATMENTS MARKET FOR FEMALE PATIENTS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 60 BODY CONTOURING PROCEDURES IN MALE PATIENTS, 2022 VS. 2023
• TABLE 61 BODY CONTOURING TREATMENTS MARKET FOR MALE PATIENTS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 62 BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 63 TOP 5 COUNTRIES PERFORMING NON-SURGICAL FAT REDUCTION TREATMENTS, 2018-2023
• TABLE 64 BODY CONTOURING TREATMENTS MARKET FOR NON-SURGICAL FAT REDUCTION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 65 BODY CONTOURING TREATMENTS MARKET FOR CELLULITE REDUCTION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 66 TOP 5 COUNTRIES PERFORMING LIPOSUCTION PROCEDURES, 2018-2023
• TABLE 67 BODY CONTOURING TREATMENTS MARKET FOR LIPOSUCTION, BY REGION, 2022-2029 (USD MILLION)
• TABLE 68 TOP 5 COUNTRIES PERFORMING ABDOMINOPLASTY TREATMENTS, 2018-2023
• TABLE 69 BODY CONTOURING TREATMENTS MARKET FOR ABDOMINOPLASTY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 70 BODY CONTOURING TREATMENTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 71 BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 72 BODY CONTOURING TREATMENTS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 73 BODY CONTOURING TREATMENTS MARKET FOR AESTHETIC CLINICS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 74 BODY CONTOURING TREATMENTS MARKET FOR MEDICAL SPAS & BEAUTY CENTERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 75 BODY CONTOURING TREATMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 76 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 77 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 78 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 79 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 80 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
• TABLE 81 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 82 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 83 KEY MACROINDICATORS FOR NORTH AMERICA
• TABLE 84 US: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 85 US: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 86 US: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 87 BODY CONTOURING PROCEDURES CONDUCTED IN US, 2020-2023
• TABLE 88 CANADA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 89 CANADA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 90 CANADA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 91 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 92 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 93 EUROPE: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 94 EUROPE: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 95 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
• TABLE 96 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 97 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 98 KEY MACROINDICATORS FOR EUROPE
• TABLE 99 BODY CONTOURING PROCEDURES CONDUCTED IN GERMANY, 2020-2023
• TABLE 100 GERMANY: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 101 GERMANY: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 102 GERMANY: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 103 FRANCE: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 104 FRANCE: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 105 FRANCE: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 107 BODY CONTOURING PROCEDURES CONDUCTED IN UK, 2022-2023
• TABLE 108 UK: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 109 UK: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 110 UK: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 111 BODY CONTOURING PROCEDURES CONDUCTED IN ITALY, 2020-2023
• TABLE 112 ITALY: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 113 ITALY: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 114 ITALY: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 115 BODY CONTOURING PROCEDURES CONDUCTED IN SPAIN, 2021-2023
• TABLE 116 SPAIN: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 117 SPAIN: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 118 SPAIN: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 119 REST OF EUROPE: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 120 REST OF EUROPE: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 121 REST OF EUROPE: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 122 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 123 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 124 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 125 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 126 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
• TABLE 127 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 128 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 129 KEY MACROINDICATORS FOR ASIA PACIFIC
• TABLE 130 BODY CONTOURING PROCEDURES CONDUCTED IN JAPAN, 2020-2022
• TABLE 131 JAPAN: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 132 JAPAN: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 133 JAPAN: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 134 CHINA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 135 CHINA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 136 CHINA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 137 BODY CONTOURING PROCEDURES CONDUCTED IN INDIA, 2020-2023
• TABLE 138 INDIA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 139 INDIA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 140 INDIA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 141 AUSTRALIA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 142 AUSTRALIA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 143 AUSTRALIA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 144 SOUTH KOREA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 145 SOUTH KOREA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 146 SOUTH KOREA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 147 REST OF ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 148 REST OF ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 149 REST OF ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 150 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 151 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 152 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 153 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 154 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
• TABLE 155 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 156 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 157 KEY MACROINDICATORS FOR LATIN AMERICA
• TABLE 158 BODY CONTOURING PROCEDURES CONDUCTED IN BRAZIL, 2020-2023
• TABLE 159 BRAZIL: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 160 BRAZIL: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 161 BRAZIL: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 162 MEXICO: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 163 MEXICO: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 164 MEXICO: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 165 BODY CONTOURING PROCEDURES CONDUCTED IN ARGENTINA, 2020-2023
• TABLE 166 REST OF LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 167 REST OF LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 168 REST OF LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 169 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 170 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• TABLE 171 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 172 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 173 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
• TABLE 174 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 175 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 176 KEY MACROINDICATORS FOR MIDDLE EAST & AFRICA
• TABLE 177 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BODY CONTOURING TREATMENTS MARKET
• TABLE 178 BODY CONTOURING TREATMENTS MARKET: DEGREE OF COMPETITION
• TABLE 179 BODY CONTOURING TREATMENTS MARKET: TECHNOLOGY FOOTPRINT
• TABLE 180 BODY CONTOURING TREATMENTS MARKET: GENDER FOOTPRINT
• TABLE 181 BODY CONTOURING TREATMENTS MARKET: APPLICATION FOOTPRINT
• TABLE 182 BODY CONTOURING TREATMENTS MARKET: END-USER FOOTPRINT
• TABLE 183 BODY CONTOURING TREATMENTS MARKET: REGION FOOTPRINT
• TABLE 184 BODY CONTOURING TREATMENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 185 BODY CONTOURING TREATMENTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
• TABLE 186 BODY CONTOURING TREATMENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 187 BODY CONTOURING TREATMENTS MARKET: DEALS, JANUARY 2021- AUGUST 2024
• TABLE 188 BODY CONTOURING TREATMENTS MARKET: EXPANSIONS, JANUARY 2021-AUGUST 2024
• TABLE 189 ABBVIE INC.: COMPANY OVERVIEW
• TABLE 190 ABBVIE INC.: PRODUCTS OFFERED
• TABLE 191 ABBVIE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 192 INMODE LTD.: COMPANY OVERVIEW
• TABLE 193 INMODE LTD.: PRODUCTS OFFERED
• TABLE 194 INMODE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 195 INMODE LTD.: DEALS, JANUARY 2021- AUGUST 2024
• TABLE 196 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW
• TABLE 197 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED
• TABLE 198 BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 199 CYNOSURE LUTRONIC: COMPANY OVERVIEW
• TABLE 200 CYNOSURE LUTRONIC: PRODUCTS OFFERED
• TABLE 201 CYNOSURE LUTRONIC: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 202 SISRAM MEDICAL LTD: COMPANY OVERVIEW
• TABLE 203 SISRAM MEDICAL LTD: PRODUCTS OFFERED
• TABLE 204 SISRAM MEDICAL LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 205 SISRAM MEDICAL LTD: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 206 SISRAM MEDICAL LTD: EXPANSIONS, JANUARY 2021-AUGUST 2024
• TABLE 207 CUTERA, INC.: COMPANY OVERVIEW
• TABLE 208 CUTERA, INC.: PRODUCTS OFFERED
• TABLE 209 CUTERA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 210 EL.EN. S.P.A.: COMPANY OVERVIEW
• TABLE 211 EL.EN. S.P.A.: PRODUCTS OFFERED
• TABLE 212 EL.EN. S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 213 VENUS CONCEPT: COMPANY OVERVIEW
• TABLE 214 VENUS CONCEPT: PRODUCTS OFFERED
• TABLE 215 VENUS CONCEPT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 216 VENUS CONCEPT: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 217 SHARPLIGHT TECHNOLOGIES INC.: COMPANY OVERVIEW
• TABLE 218 SHARPLIGHT TECHNOLOGIES INC.: PRODUCTS OFFERED
• TABLE 219 SHARPLIGHT TECHNOLOGIES INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 220 SCITON: COMPANY OVERVIEW
• TABLE 221 SCITON: PRODUCTS OFFERED
• TABLE 222 SCITON: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 223 CANDELA CORPORATION: COMPANY OVERVIEW
• TABLE 224 CANDELA CORPORATION: PRODUCTS OFFERED
• TABLE 225 CANDELA CORPORATION: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 226 BTL INDUSTRIES: COMPANY OVERVIEW
• TABLE 227 BTL INDUSTRIES: PRODUCTS OFFERED
• TABLE 228 BTL INDUSTRIES: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 229 BTL INDUSTRIES: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 230 FOTONA: COMPANY OVERVIEW
• TABLE 231 FOTONA: PRODUCTS OFFERED
• TABLE 232 FOTONA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 233 GZ MTS ELECTRONICS CO., LTD.: COMPANY OVERVIEW
• TABLE 234 GZ MTS ELECTRONICS CO., LTD.: PRODUCTS OFFERED
• TABLE 235 ROHRER AESTHETICS, INC.: COMPANY OVERVIEW
• TABLE 236 ROHRER AESTHETICS, INC.: PRODUCTS OFFERED
• TABLE 237 ROHRER AESTHETICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 238 ROHRER AESTHETICS, INC.: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 239 GBS INTERNATIONAL HOLDING LTD.: COMPANY OVERVIEW
• TABLE 240 SINCLAIR: COMPANY OVERVIEW
• TABLE 241 THERMI: COMPANY OVERVIEW
• TABLE 242 YOLO MEDICAL INC.: COMPANY OVERVIEW
• TABLE 243 DOMINION AESTHETIC TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 244 ZIMMER MEDIZINSYSTEME GMBH: COMPANY OVERVIEW
• TABLE 245 ERCHONIA CORPORATION: COMPANY OVERVIEW
• TABLE 246 CLASSYS INC.: COMPANY OVERVIEW
• TABLE 247 WON TECH CO., LTD.: COMPANY OVERVIEW
• TABLE 248 CELLSOUND AESTHETICS: COMPANY OVERVIEW

List of Figures

• FIGURE 1 BODY CONTOURING TREATMENTS MARKET SEGMENTATION
• FIGURE 2 BODY CONTOURING TREATMENTS MARKET: RESEARCH DESIGN
• FIGURE 3 BODY CONTOURING TREATMENTS MARKET: KEY PRIMARY SOURCES (DEMAND- AND SUPPLY-SIDE PARTICIPANTS)
• FIGURE 4 BODY CONTOURING TREATMENTS: KEY INSIGHTS FROM PRIMARY INTERVIEWS
• FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
• FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 7 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
• FIGURE 8 BODY CONTOURING TREATMENTS MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION
• FIGURE 9 BODY CONTOURING TREATMENTS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
• FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 11 DATA TRIANGULATION METHODOLOGY
• FIGURE 12 BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 BODY CONTOURING TREATMENTS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 16 BODY CONTOURING TREATMENTS MARKET, BY REGION, 2024-2029 (CAGR)
• FIGURE 17 GROWING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES TO DRIVE MARKET
• FIGURE 18 NON-INVASIVE TECHNOLOGIES SEGMENT TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
• FIGURE 19 AESTHETIC CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
• FIGURE 20 ABDOMINOPLASTY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 21 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
• FIGURE 22 BODY CONTOURING TREATMENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 23 NON-SURGICAL PROCEDURES PERFORMED GLOBALLY, 2023 VS. 2022
• FIGURE 24 BODY CONTOURING TREATMENTS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 25 BODY CONTOURING TREATMENTS MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 26 BODY CONTOURING TREATMENTS MARKET: ECOSYSTEM ANALYSIS
• FIGURE 27 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES
• FIGURE 28 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
• FIGURE 29 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES
• FIGURE 30 INVESTMENT AND FUNDING SCENARIO IN BODY CONTOURING TREATMENTS MARKET, 2019-2023 (USD MILLION)
• FIGURE 31 NUMBER OF INVESTOR DEALS IN BODY CONTOURING TREATMENTS MARKET, BY KEY PLAYER, 2019-2023 (UNIT)
• FIGURE 32 VALUE OF INVESTOR DEALS IN BODY CONTOURING TREATMENTS MARKET, BY KEY PLAYER, 2018-2022 (USD MILLION)
• FIGURE 33 AVERAGE SELLING PRICE OF KEY PLAYERS, BY TECHNOLOGY, 2024
• FIGURE 34 AVERAGE SELLING PRICE OF BODY CONTOURING DEVICES, BY REGION, 2024
• FIGURE 35 BODY CONTOURING TREATMENTS MARKET: PATENT ANALYSIS, 2014-2024
• FIGURE 36 BODY CONTOURING TREATMENTS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 37 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BODY CONTOURING PRODUCTS
• FIGURE 38 KEY BUYING CRITERIA, BY END USER
• FIGURE 39 NEW REVENUE POCKETS FOR PLAYERS IN BODY CONTOURING TREATMENTS MARKET
• FIGURE 40 MARKET POTENTIAL OF AI/GENERATIVE AI ON BODY CONTOURING TREATMENTS MARKET
• FIGURE 41 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET SNAPSHOT
• FIGURE 42 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET SNAPSHOT
• FIGURE 43 REVENUE ANALYSIS OF TOP PLAYERS IN BODY CONTOURING TREATMENTS MARKET, 2019-2023
• FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
• FIGURE 45 RANKING OF KEY PLAYERS IN BODY CONTOURING TREATMENTS MARKET, 2023
• FIGURE 46 BODY CONTOURING TREATMENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 47 BODY CONTOURING TREATMENTS MARKET: COMPANY FOOTPRINT
• FIGURE 48 BODY CONTOURING TREATMENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 50 EV/EBITDA OF KEY VENDORS
• FIGURE 51 BODY CONTOURING TREATMENTS MARKET: BRAND/PRODUCT COMPARISON
• FIGURE 52 ABBVIE INC.: COMPANY SNAPSHOT (2023)
• FIGURE 53 INMODE LTD.: COMPANY SNAPSHOT (2023)
• FIGURE 54 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2023)
• FIGURE 55 SISRAM MEDICAL LTD: COMPANY SNAPSHOT (2023)
• FIGURE 56 CUTERA, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 57 EL.EN. S.P.A.: COMPANY SNAPSHOT (2023)
• FIGURE 58 VENUS CONCEPT: COMPANY SNAPSHOT (2023)

The global body contouring treatments market is expected to reach USD 2.58 billion by 2029 from USD 1.46 billion in 2024, at a CAGR of 10.0% from 2024 to 2029. Increase in acceptance of aesthetic procedures, coupled with personalized and flexible financing plans has increased the demand for these products. Growing interest in anti-aging procedures are more prevalent in aging population. Body contouring procedures helps to reshape and improvesconfidence. Moreover,increased benefits of minimally invasive and non-invasive body contouring procedures have driven demand for body contouring treatments market.

"The non-invasive technologies segment of technology segment held the largest share of the market in 2023"

The body contouring treatments market is segmented based on technology into invasive technologies and non-invasive technologies. The non-invasive technologies accounted for a major share in 2023. Increase in technological innovations, rise in advertisement, and the rising adoption of devices due to less incisions is anticipated to fuel the growth of the segment. Treatments for non-invasive body contouring that involve radiofrequency, ultrasound, cryolipolysis (freezing fat), and laser-based techniques have significantly improved in tems of safety and effectiveness. These technologies have a wide range of benefits, which contribute to the non-invasive treatment popularity among individuals.

"The non-surgical fat reduction segment of application segment held the largest share of the market in 2023"

The body contouring treatments market can be segmented based on application into abdominoplasty, liposuction, non-invasive fat reduction, cellulite treatment, and other applications. Increasing number of beauty centers and rising adoption mainly due to improved accuracy and better outcomes drives the market. The non-surgical fat reduction treatments are gaining popularity across all patient types and ages. Hence, broader acceptance for treatment procedures due to innovative technologies supports the surge in demand that further drives the growth for the non-surgical fat reduction segment.

"The female patients segment for patient type segment to hold the largest market share in 2023".

Based on patient type , the body contouring treatments market is segmented into female patients and male patients. Female patients is the major segment, accounting for the largest body contouring treatments market share in 2023. The increase in awareness about non-invasive body contouring procedures, rise in post-pregnancy body reconstruction procedures, increase in influencer endorsements, and social media promotion supports the growth of the segment.

"The aesthetic clinics segment for the end user segment is projected to register a significant CAGR during the forecast period."

The body contouring treatments market is segmented by end-users into hospitals, aesthetic clinics, and medical spas & beauty centers. The hospitals accounted for a major end-user market share in 2023. The increase in spending on body shaping procedures and rise in medical tourism, and rising disposable income per capita is anticipated to propel the segment growth. Furthermore, rising adoption of new and improved devices in the hopsitals is expected to support the growth of this segment.

"The market in the Asia Pacific region is expected to witness the highest growth during the forecast period."

The north america region accounted for major share in 2023. Asia pacific region to grow at the highest CAGR in body contouring treatments market. Healthcare infrastructure and service investments, especially in the emerging economies, are fostering the development of medical aesthetics, which leads to growing demand for body contouring. In this regard, market leaders have increased their efforts to strengthen their presence in the Asia Pacific market to meet the ever-growing requirement for body contouring treatment. The availability and accessibility of the service in this market have also been enhanced by the increasing presence of aesthetic clinics, particularly in the APAC region.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
• By Designation: Director-level-10%, C-level-14%, and Others-76%
• By Region: North America-40%, Europe-30%, Asia Pacific-22%, Latin America-6%, and RoW- 10%

The prominent players in the body contouring treatments market are as AbbVie Inc. (US), InMode Ltd. (Israel), Bausch Health Companies Inc. (Canada), Cynosure Lutronic (US), Venus Concept (Canada), EL.EN.S.P.A (Italy), Sisram Medical Ltd. (Israel), BTL Industries(UK), Sharplight Technologies Inc. (Canada), Sciton Inc. (US), Candela Corporation (US), Fotona (Solvenia )

The study includes as in-depth competitive analysis of these key players in the authentication and brand protection market, with their company profiles recent developments,and key market stratergies

Research Coverage

This report studies the body contouring treatments market based on technology, application, patient type, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall body contouring treatments market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

• Analysis of key drivers (Growing adoption for minimally invasive and non-invasive body contouring procedure, increasing demand for aesthetic treatments among men, rising adoption of new and innovative body contouring technologies , broad acceptance of aesthetic procedure and growing attention on appearance and body image), restraints (high cost of treatment and inadequate reimbursement policies), opportunities (growth potential in emerging economies), and challenges (social and cultural barrriers in emerging economies, stringent regulatory compliance and safety standards) influencing the growth of the body contouring treatments market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the body contouring treatments market
• Market Development: Comprehensive information about lucrative markets-the report analyses the body contouring treatments market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the body contouring treatments market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players, such as AbbVie Inc. (US), Inmode Ltd. (Israel), Bausch Health Companies Inc. (Canada), Cynosure Lutronic (US), Sisram Medical Ltd (Israel)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS AND EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 MARKETS COVERED
  • 1.4.2 YEARS CONSIDERED
  • 1.4.3 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 IMPACT OF AI/GEN AI

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources for secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Company revenue estimation approach
    • 2.2.1.2 Customer-based market estimation
    • 2.2.1.3 Growth forecast approach
    • 2.2.1.4 CAGR projections
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 RESEARCH ASSUMPTIONS
  • 2.5.1 PARAMETRIC ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BODY CONTOURING TREATMENTS MARKET OVERVIEW
• 4.2 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY
• 4.3 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY END USER
• 4.4 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION
• 4.5 GEOGRAPHIC SNAPSHOT OF BODY CONTOURING TREATMENTS MARKET

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing adoption of minimally invasive and non-invasive body contouring procedures
    • 5.2.1.2 Increasing demand for aesthetic treatments among men
    • 5.2.1.3 Rising adoption of new and innovative body contouring technologies
    • 5.2.1.4 Widespread social media influence and cultural changes
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of treatment and inadequate reimbursement policies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth potential in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Social and cultural barriers
    • 5.2.4.2 Stringent regulatory compliance and safety standards
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 RESEARCH & PRODUCT DEVELOPMENT
  • 5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
  • 5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
• 5.4 SUPPLY CHAIN ANALYSIS
  • 5.4.1 MANUFACTURERS
    • 5.4.1.1 Prominent companies
    • 5.4.1.2 Small and medium-sized enterprises
  • 5.4.2 END USERS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 REGULATORY ANALYSIS
  • 5.6.1 REGULATORY LANDSCAPE
    • 5.6.1.1 North America
      • 5.6.1.1.1 US
      • 5.6.1.1.2 Canada
    • 5.6.1.2 Europe
    • 5.6.1.3 Asia Pacific
      • 5.6.1.3.1 Japan
      • 5.6.1.3.2 China
      • 5.6.1.3.3 India
    • 5.6.1.4 Latin America
      • 5.6.1.4.1 Brazil
  • 5.6.2 REGULATORY APPROVALS
  • 5.6.3 KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.7 REIMBURSEMENT SCENARIO ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY TECHNOLOGY
  • 5.9.2 AVERAGE SELLING PRICE OF BODY CONTOURING DEVICES, BY REGION
• 5.10 TRADE ANALYSIS
  • 5.10.1 IMPORT DATA
  • 5.10.2 EXPORT DATA
• 5.11 PATENT ANALYSIS
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 THREAT OF SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF SUPPLIERS
  • 5.12.4 BARGAINING POWER OF BUYERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA
• 5.14 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 IMPROVED FAT REDUCTION PROCEDURES USING LARGER APPLICATOR
  • 5.15.2 ENHANCED SUPPLY CHAIN AND OPERATIONAL EFFICIENCY WITH HIGHER RESEARCH & DEVELOPMENT
• 5.16 TECHNOLOGY ANALYSIS
  • 5.16.1 KEY TECHNOLOGIES
    • 5.16.1.1 Thermal technologies
    • 5.16.1.2 Non-thermal technologies
  • 5.16.2 COMPLEMENTARY TECHNOLOGIES
    • 5.16.2.1 Skin cooling systems
  • 5.16.3 ADJACENT TECHNOLOGIES
    • 5.16.3.1 Treatment planning software
• 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.18 UNMET NEEDS
• 5.19 IMPACT OF AI/GEN AI ON BODY CONTOURING TREATMENTS MARKET
  • 5.19.1 KEY USE CASES

6 BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY

• 6.1 INTRODUCTION
• 6.2 INVASIVE TECHNOLOGIES
  • 6.2.1 INVASIVE RADIOFREQUENCY TECHNOLOGY
    • 6.2.1.1 Growing inclination toward skin tightening to propel market
  • 6.2.2 INVASIVE LASER TECHNOLOGY
    • 6.2.2.1 Higher advantages compared to traditional techniques to speed up growth
  • 6.2.3 INVASIVE ULTRASOUND TECHNOLOGY
    • 6.2.3.1 Targeted fat reduction and minimal discomfort to augment growth
• 6.3 NON-INVASIVE TECHNOLOGIES
  • 6.3.1 NON-INVASIVE RADIOFREQUENCY TECHNOLOGY
    • 6.3.1.1 Rising use of cellulite treatment, fat reduction, and skin tightening to drive market
  • 6.3.2 NON-INVASIVE LASER TECHNOLOGY
    • 6.3.2.1 Growing adoption in hospitals and aesthetic clinics to fuel market
  • 6.3.3 NON-INVASIVE ULTRASOUND TECHNOLOGY
    • 6.3.3.1 Need for precise temperature management control to accelerate growth
  • 6.3.4 CRYOLIPOLYSIS TECHNOLOGY
    • 6.3.4.1 Low risk and minimal side effects to facilitate growth
  • 6.3.5 OTHER NON-INVASIVE TECHNOLOGIES

7 BODY CONTOURING TREATMENTS MARKET, BY GENDER

• 7.1 INTRODUCTION
• 7.2 FEMALE PATIENTS
  • 7.2.1 GROWING USE OF BODY CONTOURING TO ADDRESS POST-SURGICAL CHANGES TO BOOST MARKET
• 7.3 MALE PATIENTS
  • 7.3.1 INCREASING SHIFT IN SOCIAL AND AESTHETIC STANDARDS TO EXPEDITE GROWTH

8 BODY CONTOURING TREATMENTS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 NON-SURGICAL FAT REDUCTION
  • 8.2.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES TO FUEL MARKET
• 8.3 CELLULITE REDUCTION
  • 8.3.1 RISING OBESITY RATES TO SUPPORT MARKET GROWTH
• 8.4 LIPOSUCTION
  • 8.4.1 GROWING DEMAND FOR COSMETIC ENHANCEMENT WITH SHORTER RECOVERY TIMES TO DRIVE MARKET
• 8.5 ABDOMINOPLASTY
  • 8.5.1 INCREASING DESIRE FOR AESTHETIC IMPROVEMENTS TO PROMOTE GROWTH
• 8.6 OTHER APPLICATIONS

9 BODY CONTOURING TREATMENTS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS
  • 9.2.1 BOOMING MEDICAL TOURISM TO CONTRIBUTE TO MARKET GROWTH
• 9.3 AESTHETIC CLINICS
  • 9.3.1 GROWING ESTABLISHMENT OF SPECIALTY CLINICS TO DRIVE MARKET
• 9.4 MEDICAL SPAS & BEAUTY CENTERS
  • 9.4.1 RISING FOCUS ON BODY APPEARANCE TO AID GROWTH

10 BODY CONTOURING TREATMENTS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Growing public acceptance of body contouring procedures to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Rising inclination toward reducing signs of aging to aid growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Increasing volume of aesthetic procedures to drive market
  • 10.3.3 FRANCE
    • 10.3.3.1 Increasing demand for age-related aesthetic treatments to spur growth
  • 10.3.4 UK
    • 10.3.4.1 Rising focus of men on body aesthetics to encourage growth
  • 10.3.5 ITALY
    • 10.3.5.1 Gowing adoption of surgical procedures among young females to boost market
  • 10.3.6 SPAIN
    • 10.3.6.1 Growing availability of high-quality and effective products to fuel market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Presence of medical aesthetic associations to spur growth
  • 10.4.3 CHINA
    • 10.4.3.1 Increased availability of cosmetic surgery apps and online services to support growth
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing disposable income to contribute to market growth
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Favorable government initiatives to promote growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Rising influx of foreign patients to facilitate growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Heightened awareness regarding body contouring enhancements to stimulate growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Increase in patient inflow from US to sustain growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 GROWING AVAILABILITY OF HIGH-QUALITY TREATMENTS TO DRIVE MARKET
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BODY CONTOURING TREATMENTS MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Technology footprint
    • 11.5.5.3 Gender footprint
    • 11.5.5.4 Application footprint
    • 11.5.5.5 End-user footprint
    • 11.5.5.6 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.7.1 COMPANY VALUATION
  • 11.7.2 FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 ABBVIE INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches and approvals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 INMODE LTD.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches and approvals
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 BAUSCH HEALTH COMPANIES INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches and approvals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 CYNOSURE LUTRONIC
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 SISRAM MEDICAL LTD
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches and approvals
      • 12.1.5.3.2 Deals
      • 12.1.5.3.3 Expansions
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 CUTERA, INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches and approvals
  • 12.1.7 EL.EN. S.P.A.
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
      • 12.1.7.2.1 Product launches and approvals
  • 12.1.8 VENUS CONCEPT
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches and approvals
      • 12.1.8.3.2 Deals
  • 12.1.9 SHARPLIGHT TECHNOLOGIES INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches and approvals
  • 12.1.10 SCITON
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches and approvals
  • 12.1.11 CANDELA CORPORATION
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
  • 12.1.12 BTL INDUSTRIES
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product launches and approvals
      • 12.1.12.3.2 Deals
  • 12.1.13 FOTONA
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches and approvals
  • 12.1.14 GZ MTS ELECTRONICS CO., LTD.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 ROHRER AESTHETICS, INC.
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Product launches and approvals
      • 12.1.15.3.2 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 GBS INTERNATIONAL HOLDING LTD.
  • 12.2.2 SINCLAIR
  • 12.2.3 THERMI
  • 12.2.4 YOLO MEDICAL INC.
  • 12.2.5 DOMINION AESTHETIC TECHNOLOGIES, INC.
  • 12.2.6 ZIMMER MEDIZIN SYSTEME GMBH
  • 12.2.7 ERCHONIA CORPORATION
  • 12.2.8 CLASSYS INC.
  • 12.2.9 WON TECH CO., LTD.
  • 12.2.10 CELLSOUND AESTHETICS

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS